Targeted Radiopharmaceutical Delivery Platform
StarRay’s proprietary Targeted Radiopharmaceutical Delivery Platform is a novel, carrier-based system that integrates nanocarrier technology with targeted radionuclide therapy. It is designed to substantially increase the effective accumulation of radiopharmaceuticals in tumors while minimizing radiation exposure to surrounding healthy tissues.
Oncology
The platform is primarily intended for solid tumors and metastatic lesions. Its highly adaptable design is compatible with multiple clinically validated targets used in radiopharmaceutical development. Designed with clinical translation in mind, the platform integrates readily with established radioligand therapy (RLT) diagnostic and therapeutic workflows.
Core Technical Advantages
Built on a modular architecture, the platform offers the following core capabilities:
-
Flexible Radioisotope-Loading Architecture
The carrier architecture supports the flexible incorporation of a broad range of radioisotopes, enabling rapid selection among radionuclides with distinct physical properties to address evolving clinical needs. This flexibility facilitates the efficient refinement and optimization of therapeutic strategies.
-
Integrated Theranostics
Designed around a “diagnosis-first, treatment-guided” paradigm, the platform is compatible with both diagnostic and therapeutic radioisotopes, enabling an integrated approach to personalized precision radionuclide therapy.
-
Targeted Radioisotope Delivery
Through the incorporation of targeting ligands, the platform enables selective accumulation of radioactive payloads in tumors, thereby increasing the tumor-to-normal-tissue dose ratio and broadening the therapeutic window.
-
Built-in Safety Features
The unique carrier architecture helps retain radionuclides and their radioactive decay products, thereby reducing systemic radiation exposure and enhancing overall treatment safety.
